Luis Flavio Fabrini Paleare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis Flavio Fabrini Paleare has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Gustavo Leite Franklin
Universidade Federal do Paraná, Setor de Ciências da Saúde, Departamento de Medicina Interna, Curitiba PR, Brazil
2 shared publications - Hélio Afonso Ghizoni Teive
Movement Disorders Unit, Neurology Service, Internal Medicine Department Hospital de Clínicas, Federal University of Paraná Curitiba Brazil
2 shared publications - Marcio Yuri Ferreira
Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, NY
2 shared publications - Adnan Mujanovic
University Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern Inselspital, University of Bern, Bern, Switzerland
1 shared publication - Adrielle Holler Pykocz
Physiology Department, Federal University of Paraná, Curitiba, Brazilhttps://orcid.org
1 shared publication - Ahmet Günkan
Department of Radiology and Imaging Sciences, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, USA
1 shared publication
Latest Publications
- Open Access
- 23 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (04) , 001-004
Ozzy Osbourne and Parkinson's disease: from darkness to awareness
Ozzy Osbourne, the legendary frontman of Black Sabbath, publicly revealed his diagnosis of Parkinson's disease (PD) in 2020, offering visibility to a complex neurodegenerative condition. His case, later linked to a mutation in the PARK2 (parkin) gene, presented atypically with a later age of onset, contributing to ongoing discussions about the phenotypic variability of genetic forms of PD. Beyond medical narratives, Osbourne's openness and philanthropy—culminating in a benefit concert that raised $190 million for Parkinson's and pediatric charities—played a transformative role in destigmatizing the disease. This article explores the scientific and social impact of Osbourne's disclosure, highlighting the role of PARK2 in mitochondrial homeostasis, synaptic integrity, and tumor suppression. We also examine his pursuit of experimental stem cell therapy, discussing its scientific basis, ethical considerations, and current clinical research landscape.
- 23 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (04) , 001-004
Open AccessOzzy Osbourne and Parkinson's disease: from darkness to awareness
Ozzy Osbourne, the legendary frontman of Black Sabbath, publicly revealed his diagnosis of Parkinson's disease (PD) in 2020, offering visibility to a complex neurodegenerative condition. His case, later linked to a mutation in the PARK2 (parkin) gene, presented atypically with a later age of onset, contributing to ongoing discussions about the phenotypic variability of genetic forms of PD. Beyond medical narratives, Osbourne's openness and philanthropy—culminating in a benefit concert that raised $190 million for Parkinson's and pediatric charities—played a transformative role in destigmatizing the disease. This article explores the scientific and social impact of Osbourne's disclosure, highlighting the role of PARK2 in mitochondrial homeostasis, synaptic integrity, and tumor suppression. We also examine his pursuit of experimental stem cell therapy, discussing its scientific basis, ethical considerations, and current clinical research landscape.
- Open Access
- 27 February 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (02) , 001-005
Cerebral palsy in art and literature throughout history
Cerebral palsy (CP), a term coined by William John Little in 1843, represents a group of non-progressive motor disorders resulting from early brain injury. Beyond its medical characterization, there were early artistic depictions, such as Egyptian reliefs and medieval religious scenes, portraying individuals with asymmetric or contracted limbs mainly through symbolic or moral lenses. During the Renaissance and Baroque periods, artists including Dürer and Velázquez subtly represented physical diversity, though without explicit medical context. Literary portrayals evolved from mythological or moral allegory (e.g., Hephaestus, hagiographies) to empathetic narratives of individuality and inclusion, as seen in Tiny Tim, present in A Christmas Carol, written by Charles Dickens, and Draper's Out of My Mind. In modern times, artists and writers living with CP transformed disability into a means of self-expression and social critique.
- 27 February 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (02) , 001-005
Open AccessCerebral palsy in art and literature throughout history
Cerebral palsy (CP), a term coined by William John Little in 1843, represents a group of non-progressive motor disorders resulting from early brain injury. Beyond its medical characterization, there were early artistic depictions, such as Egyptian reliefs and medieval religious scenes, portraying individuals with asymmetric or contracted limbs mainly through symbolic or moral lenses. During the Renaissance and Baroque periods, artists including Dürer and Velázquez subtly represented physical diversity, though without explicit medical context. Literary portrayals evolved from mythological or moral allegory (e.g., Hephaestus, hagiographies) to empathetic narratives of individuality and inclusion, as seen in Tiny Tim, present in A Christmas Carol, written by Charles Dickens, and Draper's Out of My Mind. In modern times, artists and writers living with CP transformed disability into a means of self-expression and social critique.
- 9 January 2026
- Published by Springer Nature in Tissue Engineering and Regenerative Medicine
- Vol. 23 (2) , 221-236
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies
Background Although traumatic brain injury (TBI) is a significant cause of morbidity and mortality worldwide, there have been few significant therapeutic advances in recent years. Preclinical studies have explored the potential of adipose-derived stem cells (ADSCs) to improve neural function and reduce brain damage in animal models following TBI. This systematic review aims to assess and synthesize the current evidence on the efficacy of ADSCs in animal models with induced TBI. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Scopus, PubMed, Web of Science, and Cochrane Library from inception to July 7, 2024, for original, English-language studies on animal models of induced TBI treated with ADSCs. We excluded in vitro, in silico, studies involving humans, and conference abstracts. Risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. Results Twenty-two studies met the inclusion criteria. The most common routes of ADSC administration were intravenous and intracerebral injections, typically given within 24 h of induced TBI. Histological and neuroimaging assessments showed reduced tissue swelling and interstitial fluid accumulation in ADSC-treated animals, indicating decreased brain vasogenic edema. ADSC treatment also reduced neuroinflammation markers, suggesting lower activation of astrocytes and microglia around the injury site associated with M2 microglial phenotype polarization. Enhanced neurogenesis was observed, particularly in the hippocampus, with markers like bromodeoxyuridine (BrdU) and neuronal nuclei (NeuN) indicating improved neuron formation. Consistent cognitive and motor improvements were also noted, with treated animals showing shorter escape times and path lengths in spatial memory tests (e.g., Morris Water Maze) and better motor coordination in beam tests. Conclusion The available pre-clinical in vivo evidence indicates that ADSC-based therapies have the potential to mitigate neuroinflammation, reduce brain edema, enhance neurogenesis, and improve functional outcomes following induced TBI. Clinical studies are warranted to investigate the use of ADSCs in the treatment of TBI in humans.
- 9 January 2026
- Published by Springer Nature in Tissue Engineering and Regenerative Medicine
- Vol. 23 (2) , 221-236
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies
Background Although traumatic brain injury (TBI) is a significant cause of morbidity and mortality worldwide, there have been few significant therapeutic advances in recent years. Preclinical studies have explored the potential of adipose-derived stem cells (ADSCs) to improve neural function and reduce brain damage in animal models following TBI. This systematic review aims to assess and synthesize the current evidence on the efficacy of ADSCs in animal models with induced TBI. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Scopus, PubMed, Web of Science, and Cochrane Library from inception to July 7, 2024, for original, English-language studies on animal models of induced TBI treated with ADSCs. We excluded in vitro, in silico, studies involving humans, and conference abstracts. Risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. Results Twenty-two studies met the inclusion criteria. The most common routes of ADSC administration were intravenous and intracerebral injections, typically given within 24 h of induced TBI. Histological and neuroimaging assessments showed reduced tissue swelling and interstitial fluid accumulation in ADSC-treated animals, indicating decreased brain vasogenic edema. ADSC treatment also reduced neuroinflammation markers, suggesting lower activation of astrocytes and microglia around the injury site associated with M2 microglial phenotype polarization. Enhanced neurogenesis was observed, particularly in the hippocampus, with markers like bromodeoxyuridine (BrdU) and neuronal nuclei (NeuN) indicating improved neuron formation. Consistent cognitive and motor improvements were also noted, with treated animals showing shorter escape times and path lengths in spatial memory tests (e.g., Morris Water Maze) and better motor coordination in beam tests. Conclusion The available pre-clinical in vivo evidence indicates that ADSC-based therapies have the potential to mitigate neuroinflammation, reduce brain edema, enhance neurogenesis, and improve functional outcomes following induced TBI. Clinical studies are warranted to investigate the use of ADSCs in the treatment of TBI in humans.
- 2 December 2025
- Published by SAGE Publications in Interventional Neuroradiology
Bibliometric analysis of neurointerventional surgery: The scientific production of the specialty in the two leading specialty-specific journals
Introduction: In recent decades, neurovascular practice has shifted from open surgical procedures to interventional neuroradiology. Within this evolving landscape, two journals—Interventional Neuroradiology (INR) and Journal of NeuroInterventional Surgery (JNIS)—have become central platforms for disseminating impactful research. Methods: A bibliometric analysis was conducted using the Scopus database to identify the 500 most cited articles published in Interventional Neuroradiology (INR) and the Journal of NeuroInterventional Surgery (JNIS). Each article was categorized by study type, procedure, and pathology. Bibliometric data were analyzed using R and VOSviewer to map influential studies and collaborative networks within the field. Results: A total of 6813 articles were screened. The 500 most cited, comprising 439 from JNIS and 61 from INR, were analyzed. Citation counts averaged 70.71 per article, with the top-cited study reaching 371 citations. A marked increase in high-impact publications occurred from 2020 to 2024, reflecting growing output in the field. The United States led in total publications and citations. Trending topics evolved from early focuses on pediatric cases and aneurysms to current emphases on stroke, thrombectomy, flow diverters, and artificial intelligence. This was confirmed by keyword analysis, demonstrating the dominance of cerebrovascular pathology and minimally invasive techniques in recent neurointerventional research. Conclusion: This analysis highlights the central role of ischemic stroke and aneurysm treatment in neurointervention, with thrombectomy and endovascular therapies driving clinical advances. The field shows increasing global engagement and a shift toward higher-level evidence, reflecting its maturation. While foundational studies remain influential, recent research is poised to define future directions and innovation.
- 2 December 2025
- Published by SAGE Publications in Interventional Neuroradiology
Bibliometric analysis of neurointerventional surgery: The scientific production of the specialty in the two leading specialty-specific journals
Introduction: In recent decades, neurovascular practice has shifted from open surgical procedures to interventional neuroradiology. Within this evolving landscape, two journals—Interventional Neuroradiology (INR) and Journal of NeuroInterventional Surgery (JNIS)—have become central platforms for disseminating impactful research. Methods: A bibliometric analysis was conducted using the Scopus database to identify the 500 most cited articles published in Interventional Neuroradiology (INR) and the Journal of NeuroInterventional Surgery (JNIS). Each article was categorized by study type, procedure, and pathology. Bibliometric data were analyzed using R and VOSviewer to map influential studies and collaborative networks within the field. Results: A total of 6813 articles were screened. The 500 most cited, comprising 439 from JNIS and 61 from INR, were analyzed. Citation counts averaged 70.71 per article, with the top-cited study reaching 371 citations. A marked increase in high-impact publications occurred from 2020 to 2024, reflecting growing output in the field. The United States led in total publications and citations. Trending topics evolved from early focuses on pediatric cases and aneurysms to current emphases on stroke, thrombectomy, flow diverters, and artificial intelligence. This was confirmed by keyword analysis, demonstrating the dominance of cerebrovascular pathology and minimally invasive techniques in recent neurointerventional research. Conclusion: This analysis highlights the central role of ischemic stroke and aneurysm treatment in neurointervention, with thrombectomy and endovascular therapies driving clinical advances. The field shows increasing global engagement and a shift toward higher-level evidence, reflecting its maturation. While foundational studies remain influential, recent research is poised to define future directions and innovation.
- Top Cited Papers
- 1 March 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (3) , 580-590
Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials
BACKGROUND: A minority of patients with stroke qualify for intravenous thrombolysis (IVT) within 4.5-hour window. The safety and efficacy of IVT beyond this period have not been well studied. METHODS: We systematically searched MEDLINE, Embase, Cochrane, and ClinicalTrials.gov for relevant randomized clinical trials. Randomized clinical trials comparing IVT versus standard medical care in patients with ischemic stroke beyond 4.5 hours of symptom onset or last known well without mechanical thrombectomy (MT) were included. Primary outcomes were excellent (modified Rankin Scale score of 0–1) and good (modified Rankin Scale score of 0–2) functional outcomes at 90 days, symptomatic intracerebral hemorrhage (sICH), and death at 90 days. Pooled odds ratios (ORs) with 95% CIs were calculated using a random-effects model. Heterogeneity was assessed by Q test and quantified by I ² values. RESULTS: Eight randomized clinical trials (1742 patients; mean age, 69.8±9 years, 63.5% men) were included. Compared with standard medical care, IVT achieved higher rates of excellent (OR, 1.43 [95% CI, 1.17–1.75]; Q =2.30; P =0.94; I 2 =0%) and good functional outcomes (OR, 1.36 [95% CI, 1.12–1.66]; Q =2.07; P =0.96; I 2 =0%) at 90 days but also increased sICH rates (OR, 4.25 [95% CI, 1.67–10.84], Q =0.48; P =0.99; I 2 =0%). Mortality at 90 days did not significantly differ between treatment groups (OR, 1.28 [95% CI, 0.87–1.89]; Q =4.63; P =0.59; I 2 =0%). Subanalyses yielded numerically higher odds of excellent functional outcomes when patients were selected with perfusion imaging (3 studies, OR, 1.45 [95% CI, 1.08–1.94]) compared with diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch (3 studies, OR, 1.34 [95% CI, 0.94–1.91]) and when treated with tenecteplase (3 studies, OR, 1.47 [95% CI, 1.06–2.04]) compared with alteplase (5 studies, OR, 1.38 [95% CI, 1.08–1.78]). CONCLUSIONS: IVT for ischemic stroke beyond 4.5 hours, without MT, led to increased odds of excellent and good functional outcomes compared with standard medical care, despite higher odds of sICH, and a nonsignificant numerical increase in mortality.
- 1 March 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (3) , 580-590
Top Cited PapersThrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials
BACKGROUND: A minority of patients with stroke qualify for intravenous thrombolysis (IVT) within 4.5-hour window. The safety and efficacy of IVT beyond this period have not been well studied. METHODS: We systematically searched MEDLINE, Embase, Cochrane, and ClinicalTrials.gov for relevant randomized clinical trials. Randomized clinical trials comparing IVT versus standard medical care in patients with ischemic stroke beyond 4.5 hours of symptom onset or last known well without mechanical thrombectomy (MT) were included. Primary outcomes were excellent (modified Rankin Scale score of 0–1) and good (modified Rankin Scale score of 0–2) functional outcomes at 90 days, symptomatic intracerebral hemorrhage (sICH), and death at 90 days. Pooled odds ratios (ORs) with 95% CIs were calculated using a random-effects model. Heterogeneity was assessed by Q test and quantified by I ² values. RESULTS: Eight randomized clinical trials (1742 patients; mean age, 69.8±9 years, 63.5% men) were included. Compared with standard medical care, IVT achieved higher rates of excellent (OR, 1.43 [95% CI, 1.17–1.75]; Q =2.30; P =0.94; I 2 =0%) and good functional outcomes (OR, 1.36 [95% CI, 1.12–1.66]; Q =2.07; P =0.96; I 2 =0%) at 90 days but also increased sICH rates (OR, 4.25 [95% CI, 1.67–10.84], Q =0.48; P =0.99; I 2 =0%). Mortality at 90 days did not significantly differ between treatment groups (OR, 1.28 [95% CI, 0.87–1.89]; Q =4.63; P =0.59; I 2 =0%). Subanalyses yielded numerically higher odds of excellent functional outcomes when patients were selected with perfusion imaging (3 studies, OR, 1.45 [95% CI, 1.08–1.94]) compared with diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch (3 studies, OR, 1.34 [95% CI, 0.94–1.91]) and when treated with tenecteplase (3 studies, OR, 1.47 [95% CI, 1.06–2.04]) compared with alteplase (5 studies, OR, 1.38 [95% CI, 1.08–1.78]). CONCLUSIONS: IVT for ischemic stroke beyond 4.5 hours, without MT, led to increased odds of excellent and good functional outcomes compared with standard medical care, despite higher odds of sICH, and a nonsignificant numerical increase in mortality.
- 19 October 2024
- Published by Elsevier in World Neurosurgery
- Vol. 192, 140-149
The Evolving Role of Palliative Care in Older People with Glioblastoma
- 19 October 2024
- Published by Elsevier in World Neurosurgery
- Vol. 192, 140-149
The Evolving Role of Palliative Care in Older People with Glioblastoma